MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
2015 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
8.86 M |
Market Cap[1] |
$ 18.5 M |
EBITDA (LTM) |
$ -74.8 M |
P/E (LTM) |
-0.421158 |
P/S (LTM) |
8.796441 |
EPS (LTM) |
-5.01 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Curis
CRIS
|
$ 0.84 | -24.32 % | $ 11.1 M | Nasdaq Global Market | USA |
 |
Champions Oncology
CSBR
|
$ 4.79 | -0.83 % | $ 66.3 M | Nasdaq Capital Market | USA |
 |
Cytokinetics, Incorporated
CYTK
|
$ 54.5 | -14.31 % | $ 6.55 M | Nasdaq Global Select Market,SPB | USA |
 |
DiaMedica Therapeutics
DMAC
|
$ 9.03 | -16.16 % | $ 424 M | Nasdaq Capital Market | USA |
 |
Edesa Biotech
EDSA
|
$ 2.14 | -1.38 % | $ 12.1 M | Nasdaq Capital Market | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 13.88 | -8.86 % | $ 898 M | NYSE | USA |
 |
Evogene Ltd.
EVGN
|
$ 0.32 | -9.87 % | $ 2.52 M | Nasdaq Global Market |  Israel |
 |
Exelixis
EXEL
|
$ 68.71 | -5.56 % | $ 18.7 B | Nasdaq Global Select Market,SPB | USA |
 |
Xeris Pharmaceuticals
XERS
|
$ 13.16 | 25.76 % | $ 2.11 B | Nasdaq Global Select Market | USA |
 |
Fennec Pharmaceuticals
FENC
|
$ 9.35 | -9.66 % | $ 267 M | Nasdaq Capital Market | USA |
 |
AbbVie
ABBV
|
$ 288.16 | -2.26 % | $ 510 B | NYSE,SPB | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 1.58 | -5.39 % | $ 2.6 M | NYSE American | Israel |
 |
vTv Therapeutics
VTVT
|
$ 21.86 | -9.03 % | $ 86.4 M | Nasdaq Global Select Market | USA |
|
Forte Biosciences
FBRX
|
$ 76.99 | 0.03 % | $ 997 M | Nasdaq Capital Market | USA |
 |
AC Immune SA
ACIU
|
$ 2.11 | -7.86 % | $ 213 M | Nasdaq Global Market |  Schweiz |
 |
Aldeyra Therapeutics
ALDX
|
$ 0.61 | -5.56 % | $ 36.6 M | Nasdaq Global Select Market | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market |  Canada |
 |
AIM ImmunoTech
AIM
|
$ 0.15 | -4.97 % | $ 243 K | NYSE American | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 252.45 | -2.12 % | $ 15.3 B | Nasdaq Global Select Market |  Danmark |
 |
ANI Pharmaceuticals
ANIP
|
$ 69.63 | -2.83 % | $ 1.4 B | Nasdaq Global Market,SPB | USA |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.31 | -7.09 % | $ 40.9 M | NYSE American | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.24 | -10.14 % | $ 330 M | Nasdaq Global Select Market |  Britain |
 |
BridgeBio Pharma
BBIO
|
$ 74.33 | -4.57 % | $ 14.2 B | Nasdaq Global Select Market,SPB | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
$ 7.51 | -8.92 % | $ 1.58 B | Nasdaq Global Select Market | USA |
 |
Bicycle Therapeutics plc
BCYC
|
$ 3.49 | -6.18 % | $ 242 M | Nasdaq Global Select Market | Britain |
 |
Coherus BioSciences
CHRS
|
$ 0.75 | -11.77 % | $ 87.9 M | Nasdaq Global Market | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 27.01 | -20.69 % | $ 3.44 B | Nasdaq Global Select Market,SPB | USA |
 |
Cellectis S.A.
CLLS
|
$ 1.01 | -13.68 % | $ 101 M | Nasdaq Global Market |  France |
 |
BeyondSpring
BYSI
|
$ 0.65 | -4.9 % | $ 26.7 M | Nasdaq Capital Market | USA |
 |
Alkermes plc
ALKS
|
$ 44.51 | -3.01 % | $ 7.33 B | Nasdaq Global Select Market |  Irlanda |
 |
Altimmune
ALT
|
$ 1.97 | -7.31 % | $ 174 M | Nasdaq Global Market | USA |
 |
Cardiff Oncology
CRDF
|
$ 0.76 | -13.05 % | $ 50.8 M | Nasdaq Capital Market | USA |
 |
Citius Pharmaceuticals
CTXR
|
$ 0.55 | -0.07 % | $ 6.09 M | Nasdaq Capital Market | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 9.34 | -14.08 % | $ 256 M | Nasdaq Global Market,SPB | Israel |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 57.46 | -6.8 % | $ 7.69 B | Nasdaq Global Select Market,SPB | USA |
 |
Atara Biotherapeutics
ATRA
|
$ 8.04 | -3.94 % | $ 101 M | Nasdaq Global Select Market,SPB | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
$ 16.17 | -5.49 % | $ 2.17 B | Nasdaq Global Market | Canada |
 |
Cullinan Management
CGEM
|
$ 11.08 | -11.27 % | $ 668 M | Nasdaq Global Select Market | USA |
 |
BioNTech SE
BNTX
|
$ 85.83 | -5.37 % | $ 20.7 B | Nasdaq Global Select Market |  Germany |
 |
Replimune Group
REPL
|
$ 20.15 | -2.61 % | $ 1.87 B | Nasdaq Global Select Market | USA |
 |
Collegium Pharmaceutical
COLL
|
$ 25.17 | 6.34 % | $ 797 M | Nasdaq Global Select Market | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
$ 2.84 | -20.45 % | $ 37.8 M | Nasdaq Global Market | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
$ 1.27 | -8.63 % | $ 58 M | Nasdaq Capital Market | Israel |
 |
AnaptysBio
ANAB
|
$ 45.61 | -4.0 % | $ 1.32 B | Nasdaq Global Select Market,SPB | USA |
 |
Assembly Biosciences
ASMB
|
$ 19.94 | 0.35 % | $ 224 M | Nasdaq Global Select Market,SPB | USA |
 |
Adagene
ADAG
|
$ 2.02 | -16.18 % | $ 119 M | Nasdaq Global Market |  China |
 |
Benitec Biopharma
BNTC
|
$ 8.67 | -6.57 % | $ 404 M | Nasdaq Capital Market | USA |
 |
Denali Therapeutics
DNLI
|
$ 19.67 | -6.15 % | $ 3.4 B | Nasdaq Global Select Market,SPB | USA |
 |
Amarin Corporation plc
AMRN
|
$ 11.56 | -5.63 % | $ 4.8 B | Nasdaq Global Market | Irlanda |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.